BioCentury | Nov 30, 2017
Clinical News

Amplyx reports Phase I data for APX001 in fungal infections

...data from two Phase I trials in 166 healthy volunteers showing that oral and IV APX001...
...evaluating oral APX001 enrolled 46 healthy volunteers and the double-blind, placebo-controlled, European trial evaluating IV APX001...
...inhibits fungal enzyme GPI-anchored wall transfer protein 1 (GWT1). Amplyx has exclusive, worldwide rights to APX001...
BioCentury | Aug 4, 2017
Finance

Fungal flexibility

...infuse Amplyx Pharmaceuticals Inc. with enough cash to pursue multiple indications for its broad-spectrum antifungal, APX001...
...Chin said the investor syndicate wanted to ensure the company had enough capital to study APX001...
...species. The cash will be used to fund a broad Phase II proof-of-concept program for APX001...
BioCentury | Aug 2, 2017
Financial News

Amplyx raises $67M in series C

...plans to begin Phase II testing of APX001 to treat invasive aspergillosis and invasive candidiasis. APX001...
...designations in the U.S. to treat multiple fungal infections. Amplyx has exclusive, worldwide rights to APX001...
...Co. Ltd. (Tokyo:4523). Sofinnova's Anand Mehra and Lundbeckfonden's Johan Kördel will join Amplyx's board. Chris Lieu Oral APX001 Amplyx...
BioCentury | Sep 19, 2016
Clinical News

IV APX001: Phase I started

...double-blind, placebo-controlled, dose-escalation, European Phase I trial to evaluate single and multiple doses of IV APX001...
...I testing of oral APX001 this year. Last year, Amplyx gained exclusive, worldwide rights to APX001...
...Amplyx Pharmaceuticals Inc. , San Diego, Calif. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: IV APX001...
BioCentury | Jun 20, 2016
Clinical News

APX001 regulatory update

...Tokyo, Japan Product: APX001 Business: Infectious FDA granted Qualified Infectious Disease Product (QIDP) designation to APX001...
...of the broad-spectrum antifungal and plans to start clinical testing of the compound this year. APX001...
...enzyme GPI-anchored wall transfer protein 1 (GWT1). Last year, Amplyx gained exclusive, worldwide rights to APX001...
BioCentury | Nov 16, 2015
Finance

Clinical catalyst

...80-90%. If you wait, the patient is gone." COO Ciara Kennedy added that the molecule, APX001...
...hospital to home, she said. Next year, Amplyx plans to start Phase I testing of APX001...
BioCentury | Nov 12, 2015
Financial News

Amplyx raises $40.5M series B

...Ventures and undisclosed individuals. Next year, the company plans to start Phase I testing of APX001...
BioCentury | Jun 29, 2015
Company News

Apexigen Inc., 3SBio deal

...Apexigen granted 3SBio rights outside of China to SSS07 . 3SBio already held rights in China...
...declined to disclose deal terms. In March, 3SBio began a dose-escalation Phase I trial of SSS07...
BioCentury | Jun 23, 2015
Company News

3SBio gets worldwide rights to Apexigen's anti-TNF

...3SBio Inc. (HKSE:1530) received ex-China rights to SSS07 from Apexigen Inc. (San Carlos, Calif.). 3SBio already...
...disclose terms of the deal. In March, 3SBio began a dose-escalating Phase I study of SSS07...
BioCentury | Aug 12, 2013
Finance

Abiding no more

Abiding no more Unable to raise venture money when it spun out of service play Epitomics Inc. in 2010, Apexigen Inc. was able to work for three years using $2 million in seed funding plus...
Items per page:
1 - 10 of 10